Eisai, U.S.-Based SuperGen Hit Setback For Leukemia Drug
This article was originally published in PharmAsia News
Eisai's effort to develop a leukemia drug in the United States suffered a setback when its U.S. partner, SuperGen, reported the drug failed to meet clinical trial endpoints
You may also be interested in...
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
BD Diagnostics has gained emergency use authorization (EUA) for a handheld rapid COVID-19 antigen test that could play a pivotal role in fighting an ongoing surge of coronavirus outbreaks. See what US FDA commissioner Stephen Hahn said about it here.
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.